GLP-1 Drugs Are Changing the Shape of Demand — Not Just the Size of the Basket
Move over Veganuary. For anyone working in food and drink at the beginning of 2026, the rise of GLP-1 drugs medication has dominated the news agenda, and its impact is already showing up in shopper data and category performance. The sector is beginning to adapt.
The headline point is that adoption, while still relatively small, is growing quickly enough to affect purchasing behaviour in a visible way.
Uptake: The US Leads, the UK Is Catching Up
The United States provides the clearest early indication of potential impact. Surveys suggest 12–16% of American adults have tried a GLP-1 drug, with around 6–8% currently using one for diabetes or weight management. In absolute terms, that means tens of millions of consumers whose appetite and eating patterns have been biologically altered.
The UK is several years behind on the adoption curve. Data cited by The Grocer from Kantar and IGD suggests around 4% of UK households now include a GLP-1 user, roughly double the level seen a year earlier. The base remains small, but the trajectory — and the US precedent — explains why retailers and suppliers are watching closely.
What the Data Is Showing So Far
The most consistent signal internationally is lower overall food consumption.
Research from Cornell University and consumer analytics firm Numerator indicates U.S. households with a GLP-1 user reduce grocery spending by roughly 5–6% within six months of starting treatment. The impact is uneven across categories:
Categories seeing declines
- confectionery and sweet snacks
- bakery products
- savoury snacks
- quick-service restaurant visits
- alcohol and sugary drinks
Categories showing resilience or growth
- fresh fruit and vegetables
- yoghurt and fermented dairy
- lean protein foods
- functional or high-protein snacks
The pattern is consistent with the pharmacology: the drugs suppress appetite and reduce reward signals from high-calorie foods.
In the UK, the early data reported by the IGD (Institute of Grocery Distribution) show similar behaviour:
- 69% of users snack less frequently
- 35% eat out less often
- Around half say they eat fewer meals overall
That combination translates into smaller baskets and fewer impulse purchases, which have obvious implications for categories historically driven by snacking occasions.
How Retailers Are Responding
Several retailers have already begun experimenting with range architecture.
High-protein yoghurts, nutrient-dense ready meals, smaller portion formats (like the 100g steak from Ocado) and “mini-meal” concepts are appearing across private label. The thinking is straightforward: if consumers eat less, the opportunity lies in higher-quality, nutritionally efficient products rather than larger volumes.
However, the industry is still testing the right positioning. Explicit “GLP-1 friendly” labelling risks being niche or short-lived if the drugs plateau or face regulatory pressure.
The US Health Debate May Shape the Curve
Another factor to watch is the safety conversation emerging in the US. Regulators, including the U.S. Food and Drug Administration, have warned about unapproved compounded versions of GLP-1 drugs, while clinicians continue to debate potential side effects ranging from gastrointestinal complications to muscle loss.
None of these issues has fundamentally slowed adoption yet, but they may influence how long consumers stay on treatment and how widely the drugs are prescribed outside the US.
The Overlooked Question: What Happens After Treatment?
For the food industry, perhaps the most important unknown is post-treatment behaviour.
Clinical studies show many patients regain weight after stopping GLP-1 therapy, implying that long term use may be necessary to maintain results. But even where weight returns, behavioural patterns often change. Users report smaller portion expectations, lower tolerance for heavy, high-fat foods and a greater focus on protein and nutrient density.
In other words, habits formed during treatment may persist, even if appetite partially rebounds.
Strategic Implications for Food & Drink Brands
For brand owners, the key takeaway is not that demand will collapse — but that the composition of demand may shift.
Three implications stand out:
- Snacking occasions are under pressure, particularly high-calorie impulse products.
- Protein, fibre, and nutrient density are becoming increasingly important commercial attributes.
- Portion architecture may matter as much as formulation.
The US experience suggests the biggest risk is not falling consumption overall, but being over-indexed in the wrong types of calories.
GLP-1 adoption in the UK is still early. But the trajectory, and the signals already visible in the US, suggest this is not just a healthcare innovation. For food manufacturers and retailers, it represents a structural shift in how consumers experience hunger — and therefore how they buy food.
Simon Waring
Managing Director, Green Seed UK
To get in touch with our UK team